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Abstract
Background: Contovir is a mixture of herbal extracts (Tanacetum vulgare, Rossa canina, Urtica dioica) that is supplemented with selenium.
Objectives: This study aimed to add Contovir to the classic treatment of recurrent respiratory papillomatosis (RRP) in order to decrease the severity and extent of the disease, elongate the surgical intervals and improve the sense of patient well-being. Furthermore, we had to adjust the prescribed drug dosage, since there were no previous findings available.
Patients and Methods: This is a case study of RRP patients treated with Contovir as an adjuvant to the classic treatment, from March 2011 to February 2013, at an academic tertiary hospital (Rasoul-e-Akram hospital). All patients underwent surgical removal of papilloma and then were prescribed Contovir. Disease severity was quantified based on Derkay’s staging system.
Results: Eight patients were enrolled in this study. The extent and severity of the disease improved in six cases. One had no response, and the severity of disease increased in one patient. Patients with supraglottic lesions had better responses to Contovir adjuvant therapy. No immediate or long-term side effects were reported.
Conclusions: Although Contovir has been found to be an advantageous adjuvant for RRP treatment, further studies are called for to verify these findings.
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1. BackgroundRecurrent respiratory papillomatosis (RRP) is a recur-rent benign tumor of the respiratory tract. It is caused by genital tract human papillomaviruses (type 6 and 11 are the most common causes). This disease is transmitted during normal vaginal delivery from the infected birth canal to the respiratory tract of the child (1). The inci-dence of RRP in children is 1 - 4 per 100,000 and among adults is 1.8 - 3.9 per 100,000 (2). The major treatment modality for RRP is surgical de-bulking of papilloma by means of laser ablation or microdebridment. RRP does not cure the disease, due to papilloma regrowth after sur-gical removal. Studies have shown that approximately 4.4 procedures per year are needed for each patient with severe RRP (3). The frequent surgery requirement brings emotional and economic burdens on the patients and their families. Accordingly, laryngologists attempt to re-duce the frequency of procedures by using non-invasive modalities including supplementation with an antiviral adjuvant. The criterion for adjuvant therapy is the need 
for surgery more than four times per year (4). Clinical tri-als have shown some controlling effect of adjuvants such as interferon alfa, cidofovir, indole-3-carbinol, acyclovir, ribavirin, isotretinoin, methotrexate, the mumps vac-cine, and photodynamic therapy on RRP treatment. Inter-feron alfa and cidofovir have antiviral activities, and they also modulate the host immune response to HPV (4). Con-tovir, as a new version of an IMOD (immuno-modulatory drug), is a mixture of herbal extracts (Tanacetum vulgare, Rossa canina, Urtica dioica) supplemented with selenium, carotene and flavonoids (5, 6). The anti-inflammatory and antioxidative effects of IMODs have been shown on colitis, type 1 diabetes, pancreatic Langerhans islet trans-plantation and polycystic ovary syndrome. Previous stud-ies showed the immunostimulation and antiviral effect of IMODs in HIV-infected patients (7, 8). Safety and poten-tial mutagenic and genotoxic studies in the preclinical and clinical phase have demonstrated that IMODs are safe and non-mutagenic (6).U
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2. ObjectivesBased on the requirement for a new, safe and cost-effec-tive adjuvant, this study evaluates Contovir as a supple-ment to the classic treatment of RRP.
3. Patients and Methods
3.1. MethodsThis is a case study regarding patients with RRP, which were enrolled in a prospective follow-up using Contovir for the treatment of RRP from March 2011 to February 2013 in Rasoul-e-Akram hospital; a tertiary referral hospi-tal in Tehran, Iran affiliated with Iran University of Medi-cal Sciences. Prior to beginning the treatment with Con-tovir, patients underwent endoscopic evaluation in the operating room to locate and quantify the extent of the disease. The rate of recurrence was determined by review-ing the last 12 months of surgical history. To standardize the treatment, the surgeon discontinued all other adju-vant therapies including I3C and INF.Disease severity was quantified based on the staging system described by Derkay et al. (9) The initial dose of Contovir was 1.5 mg/kg IV. Since it causes phlebitis in children, it was administered orally. Contovir dosing was continued as: 3 mg/kg, 6 mg/kg (10th study month), 20 g/kg (16th study month).3.2. PatientsPretreatment laboratory tests were performed on all patients, including CBC diff, FBS, BUN, Cr, Na, K, liver function tests, and urinalysis. These tests were repeated before each surgery. Patients, or their parents, consented to the drug administration. In each surgery, the patient’s voice and airway condition was documented. Patients were also asked about experienced side effects.This study was approved by the institutional review 
board of Tehran University of Medical Sciences ethics committee. Written informed consent was obtained from the patients, and the study protocol conformed to the ethical guidelines of the 1975 declaration of Helsinki, as reflected in a prior approval by the institution’s hu-man research department.
4. ResultsTo evaluate the efficacy of Contovir in the treatment of RRP, nine patients were enrolled in this study. One pa-tient dropped out during follow-up, due to noncompli-ance with the medication.Demographic data for the patients are shown in Table 1. Average age at initial treatment of RRP was 3.6 years. Patients were between 2 and 56 years old. Seven patients were ≤ 15 years old. Case 1 had glottic stenosis secondary to malpractice and multiple surgeries for RRP in another center. Due to this patient’s weak responses to surgery and the medication used in this trial, we had to admin-ister INF and I3C, and after all four surgeries, his Derkay’s scores were not changed.This study included six patients who responded to Con-tovir as adjuvant therapy. The score remained constant for one patient (case 3) and was increased for another (case 1).The response appeared after the second surgery on Con-tovir (P = 0.042) and two patients showed more signifi-cant response to Contovir (cases two and six).In cases two and eight papilloma disappeared in the su-praglottis, and in cases four and seven the lesion’s exten-sion decreased in the supraglottis. This change was more visible after the second surgery on Contovir. In addition, the glottic lesions responded on the third surgery.Tracheal and subglottic papilloma did not respond to Contovir, demonstrating that only two of five patients with tracheal involvement had a decreasing tracheal score.
Table 1. The Patients’ Scores at Initiation and After Contovir Treatment, the Subunits Score and the Extension and Severity of Papil-loma
Subunits Pre Contovir 
Score
1th OP on 
Contovir
2th 3th 4th 5th 6th 7th
Patient number =1; Gender = male; Age, y = 2; Age (First presentation), y = 0.5; Total Number of Opertion in Last Year = 5; 
Comorbidity = Glottic stenosis; Tracheotomy = +
Supra glottis 22 21 6 21 12 24 6 21
Glottis 12 12 9 12 12 12 12 12
Sub glottis 3 3 3 3 3 3 3 3
Trachea 6 9 6 6 3 9 9 9
Total 43 45 24 42 30 48, (INF+I3C) 6 3020 45
Patient number =2; Gender = male; Age, y = 4; Age (First presentation), y = 1.5; Total Number of Opertion in Last Year = 4; 
Comorbidity = None; Tracheotomy = +
Supra glottis 4 0 0 0
Glottis 1 0 0 0
Un
c
rr
ct
d P
oo
f
Farhadi M et al.
3Iran Red Crescent Med J. Inpress(Inpress):e21577
Sub glottis 3 0 0 0
Trachea 6 9 4 2
Total 14 9 4 2a
Patient number = 3; Gender = female; Age, y = 15; Age (First presentation), y = 5; Total Number of Opertion in Last Year = 4; 
Comorbidity = None; Tracheotomy = +
Supra glottis 0 0 0 0
Glottis 0 0 0 0
Sub glottis 0 0 0 0
Trachea 6 9 9 6
Total 6 9 9 66
Patient number = 4; Gender = male; Age, y = 11; Age (First presentation), y = 1; Total Number of Opertion in Last Year = 3; 
Comorbidity = None; Tracheotomy = -
Supra glottis 6 3 6 1 3 6 3
Glottis 5 7 6 2 9 6 4
Sub glottis 0 0 1 0 1 3 0
Trachea 3 0 0 0 0 0 0
Total 14 10 13 3 13 15 7
Patient number = 5; Gender = male; Age, y = 56; Age (First presentation), y = 3; Total Number of Opertion in Last Year = 1; 
Comorbidity = None; Tracheotomy = -
Supra glottis 0 3 3 0 0
Glottis 6 3 3 1 0
Sub glottis 3 3 3 3 3
Trachea 6 3 3 6 9
Total 15 12 12 10 12
Patient number = 6; Gender = female; Age, y = 15; Age (First presentation), y = 13; Total Number of Opertion in Last Year = 4; 
Comorbidity = None; Tracheotomy = -
Supra glottis 0 1 0
Glottis 9 2 1
Sub glottis 0 0 0
Trachea 0 0 0
Total 9 3 1
Patient number = 7; Gender = female; Age, y = 3.5; Age (First presentation), y = 3.5; Total Number of Opertion in Last Year = 
0; Comorbidity = GE reflux; Tracheotomy = -
Supra glottis 6 6 0 2 2 0 0
Glottis 9 9 9 5 9 9 6
Sub glottis 0 0 0 0 0 0 0
Trachea 0 0 0 0 0 0 0
Total 15 15 9 7 11 9 6
Patient number = 8; Gender = female; Age, y = 9; Age (First presentation), y = 4; Total Number of Opertion in Last Year = 0; 
Comorbidity = None; Tracheotomy = -
Supra glottis 3 0 0 1
Glottis 9 9 9 8
Sub glottis 0 0 0 0
Trachea 0 0 0 0
Total 12 9 9 9aDuring one year follow up, any lesion didn’t see in laryngoscopy.
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5. DiscussionNumerous studies have been designed to evaluate the role of different adjuvants for improvement of the course of RRP. Interferon alfa is the most common adjuvant ther-apy for RRP. In one study of 60 RRP patients, Leventhal et al. reported a 78% response rate to interferon (10). Rosen et al. showed, in a study of 21 RRP patients treated with indole-3-carbinol, a complete response in 33%, a partial response in 30% and no response in 37% of patients (11). In a review of the intra lesional effect of cidofovir on RRP patients by Chadha et al., patients demonstrated 57% complete resolution, 35% partial response and 8% no im-provement (12).Despite the positive responses to these medications, their adverse effects are mentioned. Neuropsychiatric complications and bone marrow suppression are two major complications of interferon. One of its limitations is a rebound phenomenon after a primary positive re-sponse (4). In addition, intravenous cidofovir has neph-rotoxic side effects and it is potentially carcinogenic in animals (12).In our study, six of eight patients responded to Contovir. It is not understood why some patients experienced near complete remission of papilloma, whereas others had partial responses or none at all. HPV11 and tracheal lesions are two predictors of severe RRP (13). Case 1 had laryngeal comorbidity, and this patient’s HPV type was HPV11. Case 3 had only tracheal involvement. These are important characteristics to define the lack of response to Contovir. It is important to note that the response to Contovir was rapid and occurred after the second surgery.Both cases 2 and 6, who had good responses, had four surgeries in the last year . These cases showed a decrease in disease scores on the supraglottis and glottis. They were followed for one year, and their score did not in-crease. Supraglottic and glottic lesions showed better and more significant responses compared to subglottic and tracheal papilloma. No adverse effect (clinical and laboratory) was detected in this study.There are no previous studies of Contovir administra-tion for treatment of RRP. Our findings provide beneficial evidence of Contovir as an adjuvant for RRP treatment that is efficacious, well-tolerated and a noninvasive oral drug. The limitations of the present study include lack of a control group, unknown HPV typing and short-term fol-low-up. Therefore, additional studies are recommended.
5.1. ConclusionOur results show that Contovir can be a safe and effec-tive adjuvant therapy for patients with RRP, but further clinical trials are necessary before it can be recommend-ed for widespread use.
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